Ole Dragsbæk Madsen
Research Subjects
Research Interests
Ole Dragsbæk Madsen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
A. E. Sprinkel
Antibody Core, Beta Cell Biology Consortium
1 shared publicationAnne Ejrnæs Sprinkel
Antibody Core, Hagedorn Research Institute, Gentofte, Denmark
1 shared publicationC. Karlsen
Beta Cell Biology, Hagedorn Research Institute, Novo Nordisk A/S, Gentofte, Denmark
1 shared publicationC. Rescan
Hagedorn Research Institute
1 shared publicationC. Stoeckert
University of Pennsylvania
1 shared publication- Christopher V. E. Wright
Center for Stem Cell Biology, Vanderbilt University 1 , Nashville, TN 37232
1 shared publication
Latest Publications
- 23 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 55 (1) , 154-165
Pancreatic islet and progenitor cell surface markers with cell sorting potential
The aim of the study was to identify surface bio-markers and corresponding antibody tools that can be used for the imaging and immunoisolation of the pancreatic beta cell and its progenitors. This may prove essential to obtain therapeutic grade human beta cells via stem cell differentiation.
- 23 September 2011
- Published by Springer Nature in Diabetologia
- Vol. 55 (1) , 154-165
Pancreatic islet and progenitor cell surface markers with cell sorting potential
The aim of the study was to identify surface bio-markers and corresponding antibody tools that can be used for the imaging and immunoisolation of the pancreatic beta cell and its progenitors. This may prove essential to obtain therapeutic grade human beta cells via stem cell differentiation.
- 8 August 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1) , 60-68
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia
We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.
- 8 August 2011
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (s1) , 60-68
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia
We have previously reported severe anorexia abruptly induced in rats 2–3 weeks after they have been transplanted subcutaneously with the glucagonoma MSL‐G‐AN. Vagotomy did not affect the time of onset and severity of anorexia, and the anorectic state resembles hunger with strongly elevated neuropeptide Y (NPY) mRNA levels in the nucleus arcuatus. We now show that circulating levels of bioactive glucagon‐like peptide‐1 (GLP‐1) (7‐36amide) start to increase above control levels exactly at the time of onset of anorexia. At this time‐point, bioactive glucagon as well as total glucagon precursors and GLP‐1 metabolites are already vastly elevated compared to controls. We further show that intravenous administration of very high concentrations of GLP‐1 to hungry schedule‐fed rats causes anorexia in a dose‐dependent manner, which is blocked by the GLP‐1 receptor antagonist exendin (9‐39). GLP‐1 (7‐36amide) has a well‐characterized anorectic effect but also causes taste aversion when administered centrally. The anorectic effect is blocked in rats treated neonatally by monosodium glutamate (MSG). We show that MSG treatment does not prevent the MSL‐G‐AN‐induced anorexia, thereby suggesting a different type of anorectic function. We show a very strong component of taste aversion as anorectic rats, when presented to novel or known alternative food items, will resume normal feeding for 1 day, and then redevelop anorexia. We hypothetize that the anorexia in MSL‐G‐AN tumour‐bearing rats correlates with a foetal processing pattern of proglucagon to both glucagon and GLP‐1 (7‐36amide), and is due to taste aversion. The sudden onset is characterized by a dramatic increase in circulating levels of biologically active GLP‐1 (7‐36amide), suggesting eventual saturation of proteolytic inactivation of its N‐terminus.
- 20 January 2010
- Published by Springer Nature
- p. 73-81
β-Cell Ontogenesis and the Insulin Production Apparatus
- 20 January 2010
- Published by Springer Nature
- p. 73-81
β-Cell Ontogenesis and the Insulin Production Apparatus
- Open Access
- 17 March 2008
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 56 (6) , 587-595
Generation and Characterization of Ptf1a Antiserum and Localization of Ptf1a in Relation to Nkx6.1 and Pdx1 During the Earliest Stages of Mouse Pancreas Development
Ptf1a and Pdx1 are critical transcription factors of early pancreatic development, as shown by loss of function studies where lack of each gene alone causes almost complete pancreas agenesis. Ptf1a is particularly interesting because it is linked to a recently reported signature gene expression profile associated with the multipotent condition. Few useful antibody reagents have been available for consistent and reliable immunohistochemical visualization of Ptf1a protein expression in the early developing pancreas in which the level of production of this critical regulator seems to be very low. We describe a novel rabbit antibody raised against the c-terminal portion of the mouse Ptf1a protein and report immunodetection, for the first time, as early as embryonic day (e) 8.5–e8.75 in the dorsal and ventral buds of the mouse pancreas as well as in the neural tube at e10.0. Detailed confocal analysis identifies an abundant triple-positive (Ptf1a+/Nkx6.1+/Pdx1+) putative early multipotent pancreatic progenitor cell that marks the e9.5 dorsal pancreas and e10.5 ventral pancreas. Furthermore, expression patterns of Nkx6.1 vs Ptf1a subsequently segregate during branching morphogenesis (trunk vs tip), ending up marking two distinct cell populations of progenitors at e12.5. From e15.5 (mouse) and in adult pancreas (mouse, rat, and human), the Ptf1a antibody marks only acinar cell nuclei, as expected for its subsequent role in committing/maintaining cells in this differentiated state. In summary, this antibody is a novel tool to further characterize important early steps of pancreas differentiation. This manuscript contains online supplemental material at http://www.jhc.org . Please visit this article online to view these materials.
- 17 March 2008
- Published by SAGE Publications in Journal of Histochemistry & Cytochemistry
- Vol. 56 (6) , 587-595
Open AccessGeneration and Characterization of Ptf1a Antiserum and Localization of Ptf1a in Relation to Nkx6.1 and Pdx1 During the Earliest Stages of Mouse Pancreas Development
Ptf1a and Pdx1 are critical transcription factors of early pancreatic development, as shown by loss of function studies where lack of each gene alone causes almost complete pancreas agenesis. Ptf1a is particularly interesting because it is linked to a recently reported signature gene expression profile associated with the multipotent condition. Few useful antibody reagents have been available for consistent and reliable immunohistochemical visualization of Ptf1a protein expression in the early developing pancreas in which the level of production of this critical regulator seems to be very low. We describe a novel rabbit antibody raised against the c-terminal portion of the mouse Ptf1a protein and report immunodetection, for the first time, as early as embryonic day (e) 8.5–e8.75 in the dorsal and ventral buds of the mouse pancreas as well as in the neural tube at e10.0. Detailed confocal analysis identifies an abundant triple-positive (Ptf1a+/Nkx6.1+/Pdx1+) putative early multipotent pancreatic progenitor cell that marks the e9.5 dorsal pancreas and e10.5 ventral pancreas. Furthermore, expression patterns of Nkx6.1 vs Ptf1a subsequently segregate during branching morphogenesis (trunk vs tip), ending up marking two distinct cell populations of progenitors at e12.5. From e15.5 (mouse) and in adult pancreas (mouse, rat, and human), the Ptf1a antibody marks only acinar cell nuclei, as expected for its subsequent role in committing/maintaining cells in this differentiated state. In summary, this antibody is a novel tool to further characterize important early steps of pancreas differentiation. This manuscript contains online supplemental material at http://www.jhc.org . Please visit this article online to view these materials.
- Open Access
Stem cells and diabetes treatment
Diabetes mellitus types 1 and 2 are characterized by absolute versus relative lack of insulin‐producing β cells, respectively. Reconstitution of a functional β‐cell mass by cell therapy – using organ donor islets of Langerhans – has been demonstrated to restore euglycaemia in the absence of insulin treatment. This remarkable achievement has stimulated the search for appropriate stem cell sources from which adequate expansion and maturation of therapeutic β cells can be achieved. This recent activity is reviewed and presented with particular focus on directed differentiation from pluripotent embryonic stem cells (versus other stem/progenitor cell sources) based on knowledge from pancreatic β‐cell development and the parallel approach to controlling endogenous β‐cell neogenesis.
Open AccessStem cells and diabetes treatment
Diabetes mellitus types 1 and 2 are characterized by absolute versus relative lack of insulin‐producing β cells, respectively. Reconstitution of a functional β‐cell mass by cell therapy – using organ donor islets of Langerhans – has been demonstrated to restore euglycaemia in the absence of insulin treatment. This remarkable achievement has stimulated the search for appropriate stem cell sources from which adequate expansion and maturation of therapeutic β cells can be achieved. This recent activity is reviewed and presented with particular focus on directed differentiation from pluripotent embryonic stem cells (versus other stem/progenitor cell sources) based on knowledge from pancreatic β‐cell development and the parallel approach to controlling endogenous β‐cell neogenesis.